Sugi Predict

Sugi Predict / Targets / YES1

YES1

Tyrosine-protein kinase Yes · P07947 · YES1 on Sugi Atlas →

72,748 patent compounds predicted against YES1, 60,291 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL144412 SCHEMBL144412 0.80 8/20
SCHEMBL145862 SCHEMBL145862 0.65 8/20
SCHEMBL145575 SCHEMBL145575 0.47 8/20
SCHEMBL146223 SCHEMBL146223 0.68 7/20
SCHEMBL142454 SCHEMBL142454 0.68 7/20
SCHEMBL146894 SCHEMBL146894 0.63 7/20
SCHEMBL141999 SCHEMBL141999 0.62 7/20
SCHEMBL144771 SCHEMBL144771 0.59 7/20
SCHEMBL147095 SCHEMBL147095 0.55 7/20
SCHEMBL144719 SCHEMBL144719 0.54 7/20
SCHEMBL141930 SCHEMBL141930 0.90 6/20
SCHEMBL144256 SCHEMBL144256 0.88 6/20
SCHEMBL141033 SCHEMBL141033 0.75 6/20
SCHEMBL144853 SCHEMBL144853 0.75 6/20
SCHEMBL140461 SCHEMBL140461 0.72 6/20
SCHEMBL142369 SCHEMBL142369 0.72 6/20
SCHEMBL144369 SCHEMBL144369 0.62 6/20
SCHEMBL148432 SCHEMBL148432 0.62 6/20
SCHEMBL144321 SCHEMBL144321 0.61 6/20
SCHEMBL145516 SCHEMBL145516 0.59 6/20

Clinical trials — most relevant to YES1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma PHASE4RECRUITING
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer PHASE2RECRUITING
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors PHASE1/PHASE2NOT_YET_RECRUITING
Phase II Dasatinib Study in Advanced Breast Cancer PHASE2COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours PHASE1/PHASE2RECRUITING
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies PHASE1/PHASE2COMPLETED
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia PHASE2COMPLETED
Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias PHASE2WITHDRAWN
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas PHASE1/PHASE2COMPLETED
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) PHASE1COMPLETED
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Dasatinib and Crizotinib in Advanced Cancer PHASE1COMPLETED
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC PHASE1UNKNOWN
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors PHASE1COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
Primary Resistance Mechanisms of ALK TKIs nanNOT_YET_RECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors nanUNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia nanRECRUITING
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Prospective Monocentric Clinical-biological Database nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a YES1 binder may also engage these)

ProteinNameSimilarity
P10936 — 1.000 P10936 →
Q28923 — 1.000 Q28923 →
F1LM93 — 1.000 F1LM93 →
P00527 — 1.000 P00527 →
A1A5H8 — 1.000 A1A5H8 →
Q04736 — 1.000 Q04736 →
P09324 — 1.000 P09324 →
Q6EWH2 — 1.000 Q6EWH2 →
FYN Tyrosine-protein kinase Fyn 1.000 landscape →
Q62844 — 1.000 Q62844 →
P27447 — 1.000 P27447 →
A1Y2K1 — 1.000 A1Y2K1 →
LYN Tyrosine-protein kinase Lyn 1.000 landscape →
Q05876 — 1.000 Q05876 →
FGR Tyrosine-protein kinase Fgr 1.000 landscape →
P25911 — 0.999 P25911 →
Q9V9J3 — 0.998 Q9V9J3 →
P63185 — 0.998 P63185 →
P39688 — 0.998 P39688 →
P27446 — 0.997 P27446 →
P00526 — 0.997 P00526 →
P42690 — 0.997 P42690 →
Q02977 — 0.997 Q02977 →
Q5PXS1 — 0.997 Q5PXS1 →
P50545 — 0.997 P50545 →
P06240 — 0.997 P06240 →
P00523 — 0.997 P00523 →
SRC Proto-oncogene tyrosine-protein kinase Src 0.996 landscape →
Q01621 — 0.996 Q01621 →
P13115 — 0.996 P13115 →